Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408953 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue
A Phase 2 study, sponsored by Tirgan, Michael H., M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01408953 is a Phase 2 study that was terminated before completion, run by Tirgan, Michael H., M.D.. The registered enrollment target is 2 participants.
The verdict
NCT01408953, a Phase 2 study, was terminated before completion, sponsored by Tirgan, Michael H., M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life. Keloids do not regress on their own and results of most available treatments such as surgery, injecting keloids with steroids, chemotherapy injections, or even radiation therapy, have mostly proven disappointing. Some laboratory studies have shown that there is excessive amount of a protein called "vascular endothelial growth factor (VEGF)" in keloid tissue. This may play role in the formation and evolution of keloid. Bevacizumab is a drug that works by targeting vascular endothelial growth factor (VEGF) which helps new blood vessels form. Without new blood vessels, the growth of the keloid may be slowed Based on presence of excess amount of VEGF in keloid tissue, we hypothesize that bevacizumab will be effective in treatment of keloids. This exploratory clinical trial is to confirm or reject this hypothesis.
Interventions
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408953
The ClinicalTrials.gov registry entry for NCT01408953 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tirgan, Michael H., M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab is the first listed.
NCT01408953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408953 about?
NCT01408953 is a clinical study titled "Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue". Keloid is chronic skin conditions that results in formation of tumor like growths on the skin. Despite its benign nature, keloid can cause severe aesthetic and, in some cases, functional problem which negatively impacts person's quality of life. Keloids do not regress on their own and results of mo...
What is the current status of trial NCT01408953?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01408953?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01408953?
This trial is sponsored by Tirgan, Michael H., M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.